Clinical Trial: Safety and Efficacy of CEM-102 With Rifampin Compared to Standard Therapy in Patients With Prosthetic Joint Infections or Spacer Infection
Study Status: Terminated
Recruit Status: Terminated
Study Type: Interventional
Official Title:
Brief Summary: To determine if oral antibiotic treatment with CEM-102 and Rifampin is as effective and safe as the standard of care antibiotic therapy for the treatment of hip and knee prosthetic joint or spacer infections
Detailed Summary:
Sponsor: Cempra Inc
Current Primary Outcome: Bacterial eradication of joint infection [ Time Frame: 3 to 6 months ]
Original Primary Outcome: Bacterial eradication of joint infection [ Time Frame: 12 weeks ]
Current Secondary Outcome:
Original Secondary Outcome:
Information By: Cempra Inc
Dates:
Date Received: December 18, 2012
Date Started: December 2012
Date Completion:
Last Updated: November 18, 2014
Last Verified: November 2014